SCHEMBL314780

SCHEMBL314780

CC1CNc2cc(O)ccc2-n2c(-c3cccc(F)c3)nnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.35
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
PIM1 P11309 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
P2RX7 Q99572 1/20 0.32
MAOB P27338 1/20 0.32
OPRD1 P41143 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
HSD17B1 P14061 1/20 0.32
HSD17B2 P37059 1/20 0.32
HSD11B1 P28845 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314882 0.91 ALDH1A1 (0.40) KDM4EHSD17B10ALDH1A1HPGDOPRD1
SCHEMBL314883 0.91 ALDH1A1 (0.40) KDM4EHSD17B10ALDH1A1HPGDOPRD1
SCHEMBL314881 0.91 ALDH1A1 (0.40) KDM4EHSD17B10ALDH1A1HPGDOPRD1
SCHEMBL314273 0.88 TP53 (0.40) ESR2ALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL314274 0.88 TP53 (0.40) ESR2ALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL314275 0.88 TP53 (0.40) ESR2ALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL314214 0.88 HSD11B1 (0.39) KDM4EHSD17B10ALDH1A1HPGDPIM1
SCHEMBL313997 0.88 HSD11B1 (0.39) KDM4EHSD17B10ALDH1A1HPGDPIM1
SCHEMBL314215 0.88 HSD11B1 (0.39) KDM4EHSD17B10ALDH1A1HPGDPIM1
SCHEMBL314464 0.86 BRD4 (0.40) KDM4EALDH1A1HPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 ESR2 316/4885KDM4E 2733/4885HSD17B10 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.